Plasma Patents (Class 424/530)
  • Patent number: 10828326
    Abstract: This invention relates to compositions and methods for treating, ameliorating and preventing the toxic effects of venom poisoning. In particular, the invention provides compositions comprising carbon monoxide releasing molecules (CORM) or compositions comprising CORM and iron releasing molecules (IRM) for one or more of enhancing coagulation, reducing fibrinolysis, and/or inactivating venom related metalloproteinase activity in a subject suffering from or at risk of suffering from venom poisoning.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: November 10, 2020
    Assignee: Arizona Board of Regents on Behalf of the University of Arizona
    Inventors: Vance G. Nielsen, Leslie V. Boyer
  • Patent number: 10722608
    Abstract: The present disclosure is directed to blood dotting compositions comprising platelet microparticles, method of using said compositions, and methods of preparing the same.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: July 28, 2020
    Assignee: University of Rochester
    Inventor: Majed A. Refaai
  • Patent number: 10512659
    Abstract: The present disclosure relates to methods and apparatus for producing platelet rich plasma, bone marrow mononuclear cells, stromal vascular fraction from adipose tissue, and other concentrated or enriched biological fluids.
    Type: Grant
    Filed: July 2, 2016
    Date of Patent: December 24, 2019
    Assignee: Arthrex, Inc.
    Inventors: Melissa D. Tucker, Christopher Bare, Abigail Nabors, Robert Harrison
  • Patent number: 10314860
    Abstract: This invention relates to compositions and methods for treating, ameliorating and preventing the toxic effects of venom poisoning. In particular, the invention provides compositions comprising carbon monoxide releasing molecules (CORM) or compositions comprising CORM and iron releasing molecules (IRM) for one or more of enhancing coagulation, reducing fibrinolysis, and/or inactivating venom related metalloproteinase activity in a subject suffering from or at risk of suffering from venom poisoning.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: June 11, 2019
    Assignee: Arizona Board of Regents on Behalf of the University of Arizona
    Inventors: Vance G. Nielsen, Leslie V. Boyer
  • Patent number: 10124084
    Abstract: The invention provides a ready to use biodegradable and biocompatible device and a method for manufacturing thereof. The device of present invention is a novel porous scaffold which can be used as carrier of plurality of therapeutics to quickly stop bleeding and other biomaterial and biomedical application. The scaffold can be directly applied to the spot of the wound and will stop bleeding within no time. The scaffold of the present invention comprises of combined application of air dry and freeze dry method. The scaffold also comprises of excellent ventilations properties and easy removal of the scaffold without causing any extra hemorrhage to the wound.
    Type: Grant
    Filed: August 21, 2014
    Date of Patent: November 13, 2018
    Assignee: Datt Life Sciences Private Limited
    Inventors: Rajan Datt, Ramadhar Kumar, Pallavi Shrivastava
  • Patent number: 10046081
    Abstract: The invention generally relates to dextran fibers which are preferably electrospun and devices formed from such fibers. In particular, such devices may include substances of interest (such as therapeutic substances) associated with the electrospun fibers. Upon exposure to a liquid the electrospun fibers dissolve immediately and the substances of interest are released into the liquid. Exemplary devices include bandages formed from electrospun dextran fibers and associated agents that promote hemostasis, such as thrombin and fibrinogen.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: August 14, 2018
    Assignees: The Henry M Jackson Foundation for the Advancement of Military Medicine, Inc., Virginia Commonwealth University
    Inventors: Gary Bowlin, David Simpson, James Bowman, Stephen Rothwell
  • Patent number: 10036002
    Abstract: Methods and systems for activating Factor X are disclosed.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: July 31, 2018
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Meinhard Hasslacher, Thomas Gatternig, Christian Fiedler, Ernst Böhm, Michael Dockal, Franziska Horling
  • Patent number: 9956272
    Abstract: Methods for preparing Factor X, activated Factor X, inactivated factor X and inactivated factor Xa, compositions comprising Factor X and Factor Xa, inactivated Factor X and inactivated Factor Xa and methods of medical treatment using Factor X, Factor Xa, activated Factor X and inactivated Factor Xa are disclosed. The preparation methods comprise a chromatography step using an immobilised metal ion affinity chromatography substrate.
    Type: Grant
    Filed: May 29, 2008
    Date of Patent: May 1, 2018
    Assignee: Bio Products Laboratory Limited
    Inventors: Joanne Lloyd, Peter Feldman
  • Patent number: 9856467
    Abstract: Modified therapeutic proteins are provided. In particular modified Factor X polypeptides, which includes the Factor X zymogen, Factor Xa and other forms of Factor X, and uses thereof are provided.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: January 2, 2018
    Assignee: Catalyst Biosciences, Inc.
    Inventors: Edwin L. Madison, Christopher Thanos
  • Patent number: 9480716
    Abstract: The invention provides for a method of preparing an isolated serum fraction of platelet rich fibrin (PRF), comprising the steps of a. providing platelet rich plasma (PRP) without the addition of an anticoagulant; b. clotting the PRP to obtain a coagel of PRF; and c. separating the coagel to isolate the serum fraction which comprises an activated platelet releasate; and further provides for the isolated serum fraction obtained by such method, and its medical use.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: November 1, 2016
    Assignee: Lacerta Technologies Inc.
    Inventors: Zsombor Lacza, Gabriella Vácz
  • Patent number: 9370568
    Abstract: Described herein are methods and compositions for the treatment of respiratory diseases such as, for example, exercise induced pulmonary hemorrhage. The methods include the use of compositions comprising platelet enriched plasma, for example, platelet rich plasma and/or platelet poor plasma, for treatment of respiratory diseases in humans and animals, in particular, equines, by administration to the respiratory system.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: June 21, 2016
    Assignee: VetGel Technologies
    Inventor: Richard Gold
  • Patent number: 9145552
    Abstract: Modified therapeutic proteins are provided. In particular modified Factor X polypeptides, which includes the Factor X zymogen, Factor Xa and other forms of Factor X, and uses thereof are provided.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: September 29, 2015
    Assignee: Catalyst Biosciences, Inc.
    Inventors: Edwin L. Madison, Christopher Thanos
  • Publication number: 20150147319
    Abstract: A method and composition for treating or preventing antibody-mediated rejection (AMR) of a transplanted organ are provided.
    Type: Application
    Filed: November 21, 2014
    Publication date: May 28, 2015
    Inventors: Colin Broom, Marc E. Uknis
  • Publication number: 20150147300
    Abstract: Methods of inducing a polarization of macrophages. The method includes obtaining a blood fraction, fractionating the blood fraction to produce a blood fraction, and contacting the blood fraction with a source of macrophages. A blood fraction including platelet-poor plasma polarizes the source of macrophages into M1 macrophages. A blood faction including a protein solution polarizes the source of macrophages into M2 macrophages.
    Type: Application
    Filed: November 26, 2014
    Publication date: May 28, 2015
    Inventors: Jennifer E. Woodell-May, Joel C. Higgins, William King
  • Publication number: 20150125442
    Abstract: Agents, compositions, and medicaments that reduce interactions between muscle specific kinase receptor (MuSK) and pathogenic immunoglobulin G4 (IgG4) antibodies specific for the first Ig-like domain of MuSK and methods and uses thereof to reduce such interactions are encompassed herein. Also encompassed are screening assays to identify inhibitors of these pathogenic antibodies, particularly those that reduce binding to MuSK. Agents identified using the screening assays described herein are envisioned for use as therapeutics, alone or in compositions or in medicaments, to improve motor function in subjects afflicted MuSK-MG.
    Type: Application
    Filed: September 15, 2014
    Publication date: May 7, 2015
    Inventors: Steven J. Burden, Wei Zhang, Maartje Huijbers, Johannes J. Verschuuren, Silvère M. van der Maarel
  • Publication number: 20150125436
    Abstract: The present invention is related to the field of tissue regeneration. It concerns more particularly new processes, tubes and devices for thrombin, platelet concentrate and wound healant preparations, alone or in combination with cell extracts, cell compositions and uses thereof.
    Type: Application
    Filed: January 14, 2015
    Publication date: May 7, 2015
    Inventor: ANTOINE TURZI
  • Patent number: 9011929
    Abstract: The present invention relates to a composition for cartilaginous tissue repair and to a production method therefor. The present invention comprises the steps of: (a) dissolving freeze-dried fibrinogen in an aprotinin solution; (b) dissolving freeze-dried thrombin in a stabilizing solution; (c) mixing an enriched collagen solution with thrombin and the stabilizing solution; and installing the fibrinogen solution (a) to one side of a dual kit and the solution (c) containing the collagen to the other side, and then mixing and injecting into damaged cartilaginous tissue. In the present invention, which is constituted as described above, biomaterials such as collagen and fibrin are mixed so as to allow damaged cartilaginous tissue to be repaired to a state allowing transplantation onto the tissue, and efficient regeneration is induced, thereby making it possible to reduce surgery-related stress on people and animals while inducing relatively rapid and efficient cartilage repair and regeneration.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: April 21, 2015
    Assignee: Sewon Cellontech Co., Ltd.
    Inventors: Hyun-Shin Park, Ji-Chul Yu, Ju-Hee Park, Jang-Hoon Kim, Hun Kim, Sae-Bom Lee, Jae-Deog Jang, Cheong-Ho Jang
  • Publication number: 20150086536
    Abstract: A method for assessing risk of losing a transplanted organ by a patient having an episode of acute rejection of the transplanted organ is described. The method includes obtaining from the patient a cell sample from the transplanted organ or peripheral blood, determining a level of FOXP3 in the cell sample, and correlating the level with the risk of loss of the transplanted organ, wherein, compared to a control level, a significantly greater level of FOXP3 in the cell sample from the transplanted organ or a significantly lower level of FOXP3 in the cell sample from the peripheral blood correlates with a decreased risk of loss of the transplanted organ.
    Type: Application
    Filed: September 29, 2014
    Publication date: March 26, 2015
    Applicant: CORNELL RESEARCH FOUNDATION, INC.
    Inventor: Manikkam Suthanthiran
  • Publication number: 20150079194
    Abstract: Systems and methods for purification and concentration of autologous alpha-2 macroglobulin (A2M) from whole blood and or recombinant A2M are provided. Also provided are methods of treating wounds with A2M. Methods for utilizing A2M in combination with other treatments (e.g., platelets and other growth factors) are provided in addition to combinations with exogenous drugs or carriers. Also provided is a method of producing recombinant A2M wild type or variants thereof where the bait region was modified to enhance the inhibition characteristics of A2M and/or to prolong the half-life of the protein for treating wounds.
    Type: Application
    Filed: August 28, 2014
    Publication date: March 19, 2015
    Inventors: Lewis HANNA, John David LAUGHLIN, Shawn Robert BROWNING
  • Publication number: 20150079067
    Abstract: This invention discloses a method to produce a pharmaceutical composition from bloods for repairing wound which don't have to extra add commercial thrombins or non-human thrombins but to manufacture the pharmaceutical composition from bloods for repairing wound directly from bloods. Therefore, the method discloses in this present invention have the effect to avoid the rejection reaction of the treated patients and to reduce the costs of production, and furthermore to decrease medical costs and the burden of patients.
    Type: Application
    Filed: March 12, 2014
    Publication date: March 19, 2015
    Applicant: Taichung Hospital, Ministry of Health and Welfare
    Inventor: Hsin-Chung TSAI
  • Publication number: 20150071983
    Abstract: Bioactive porous bone graft implants in various forms suitable for use in bone tissue regeneration and/or repair, as well as methods of use are provided. The implants are formed of bioactive glass and have an engineered porosity. The implants may be contained in polymer for enhanced clinical results and better handling.
    Type: Application
    Filed: November 17, 2014
    Publication date: March 12, 2015
    Inventors: Charanpreet S. BAGGA, Steve B. JUNG, Hyun W. BAE
  • Publication number: 20150073476
    Abstract: The present invention relates to compositions comprising shape memory polymer (SMP) materials and uses thereof. Particularly, although not exclusively, the present invention relates to biocompatible shape memory polymer (SMP) materials and uses thereof in the medical field.
    Type: Application
    Filed: October 5, 2012
    Publication date: March 12, 2015
    Inventors: Malcolm Brown, Horacio Montes de Oca Balderas, Michael Andrew Hall, Alan William Bull, David Franklin Farrar, Philip Caton-Rose, Philip David Coates, Glen Thompson, Michael Martyn, Ian MacMillan Ward, Mark James Bonner, Peter John Hine, Paul Unwin, Robin Anthony Chivers, Michael Woodhead
  • Publication number: 20150064164
    Abstract: The present invention relates to an agent having activity in the treatment of a tissue disruption.
    Type: Application
    Filed: September 19, 2014
    Publication date: March 5, 2015
    Inventors: Jeffrey D. Edwards, Maud Louise Eijkenboom
  • Publication number: 20150064133
    Abstract: The present disclosure provides a composition comprising a bioactive fraction derived from a platelet concentrate, methods of making the bioactive fraction, and culture medium supplemented with the bioactive fraction. Preferred bioactive fractions have relatively low fibrinogen concentrations while retaining native growth factors in beneficial amounts and ratios.
    Type: Application
    Filed: August 27, 2014
    Publication date: March 5, 2015
    Inventors: Erik J. Woods, Christopher Taylor
  • Publication number: 20150037431
    Abstract: Methods and kits for treating a cardiac arrhythmia using a platelet rich plasma (PRP) composition are provided. Any type of arrhythmia may be treated using the PRP composition. The PRP composition may comprise PRP developed using blood collected from a patient suffering the cardiac arrhythmia. The PRP composition may be buffered to a physiological pH and may include one or more anti-arrhythmic agents, anti-coagulants, or other drugs. The PRP composition may be delivered using a nebulizer, minimally invasively, or surgically.
    Type: Application
    Filed: August 29, 2014
    Publication date: February 5, 2015
    Inventors: Allan Kumar Mishra, Todd Jeffrey Brinton
  • Publication number: 20150037430
    Abstract: Formulation comprising, or derived from, an initial blood composition, wherein the formulation is rich in platelets and/or growth factors and proteins originating from the initial blood composition, and wherein the proteins are in a gelled state. The invention also refers to method for preparing the formulation, comprising the steps of heating and then cooling the initial blood composition at certain temperatures and times. Among other advantages, the formulation in accordance with the invention is biocompatible and biodegradable, presents the desirable biological or medical properties provided by the presence of platelets or growth factors, and also presents high dimensional stability over time.
    Type: Application
    Filed: July 31, 2014
    Publication date: February 5, 2015
    Inventor: Eduardo ANITUA ALDECOA
  • Publication number: 20150032045
    Abstract: The present invention describes Photolabile Compounds methods for use of the compounds. The Photolabile Compounds have a photoreleasable ligand, which can be biologically active, and which is photoreleased from the compound upon exposure to light. In some embodiments, the Photolabile Compounds comprise a light antenna, such as a labeling molecule or an active derivative thereof. In one embodiment, the light is visible light, which is not detrimental to the viability of biological samples, such as cells and tissues, in which the released organic molecule is bioactive and can have a therapeutic effect. In another embodiment, the photoreleasable ligand can be a labeling molecule, such as a fluorescent molecule.
    Type: Application
    Filed: December 21, 2012
    Publication date: January 29, 2015
    Inventors: Rafael Yuste, Roberto Etchenique, Luis Baraldo
  • Publication number: 20150004245
    Abstract: In particular, a composition for breast augmentation that includes a composition promoting an increase in subcutaneous tissue, wherein the promoting composition aims at accumulating and increasing adipose tissue under the skin of a breast by generating and increasing the adipose tissue around a mammary gland and enables recovery of autologous tissue and recovery of appearance by a safe and natural process, and a method for breast augmentation are provided. A composition promoting an increase in subcutaneous tissue that contains autologous plasma and a basic fibroblast growth factor (b-FGF), in particular, a composition for breast augmentation is provided. A composition for breast augmentation that includes the above-described composition promoting an increase in subcutaneous tissue that further contains fat is provided.
    Type: Application
    Filed: February 21, 2013
    Publication date: January 1, 2015
    Inventor: Kensuke Yamakawa
  • Patent number: 8911789
    Abstract: Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: December 16, 2014
    Assignees: Carnegie Mellon University, Allegheny-Singer Research Institute, Carmell Therapeutics Corporation
    Inventors: Phil G. Campbell, James E. Burgess, Lee E. Weiss, Jason Smith
  • Publication number: 20140363403
    Abstract: The present invention provides for the harvesting of specific materials in multiple stages of filtration of bone graft materials from a reaming device, specifics of interconnected stages, related filtration materials, and techniques. The harvesting process collects large material in a first stage, and other materials of a limited geometric size in at least a second stage of filtration. Such material captured in the second stage may contain plasma, cellular elements including stem cells as well as growth factors and other particulate matter of a specific geometrically limited size, using various filtration approaches including centrifugation in some embodiments. Further embodiments of the invention provide for an improved tubing interface and management approach to ease use in the operating room. Filtration materials may include biodegradable-material based filters and may allow direct implantation of small scale and larger scale matter in specific portions within the biodegradable-material itself.
    Type: Application
    Filed: June 16, 2014
    Publication date: December 11, 2014
    Applicant: Genesis Medical Devices, LLC
    Inventors: Daniel Nick Segina, James Arthur Proctor, JR.
  • Patent number: 8900806
    Abstract: An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: December 2, 2014
    Assignee: Biotest AG
    Inventors: Wolfgang Moeller, Dieter Rudnick, Oliver Maneg, Michael Rodemer, Matthias Germer, Veit Braun
  • Publication number: 20140271779
    Abstract: Synthetic, bioactive ultra-porous bone graft materials having an engineered porosity, and implants formed from such materials are provided. In particular, these implants comprise bioactive glass and incorporate allograft material for osteoinduction. The implants are suitable for bone tissue regeneration and/or repair.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 18, 2014
    Applicant: PROSIDYAN, INC.
    Inventors: Charanpreet S. BAGGA, Steve B. JUNG, Hyun W. BAE
  • Publication number: 20140271786
    Abstract: Bioactive porous bone graft implants in various forms suitable for use in bone tissue regeneration and/or repair, as well as methods of use are provided. The implants are formed of bioactive glass and have an engineered porosity. The implants may be contained in polymer for enhanced clinical results and better handling.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 18, 2014
    Applicant: Prosidyan, Inc.
    Inventors: Charanpreet S. BAGGA, Steve B. Jung, Hyun W. Bae
  • Publication number: 20140242181
    Abstract: The present invention aims to generate a fibrin gel for cell proliferation and transport using the patient's own blood or compatible blood. The gel-preparation process consists in taking a quantity of blood from the patient, using sodium citrate as anticoagulant, separating off the citrated plasma by centrifugation, and resuspending the cells to be transported in the plasma. CaCl2 is added to the resulting suspension to form the gel (either as an isolated coagulate or within a porous chitosan, gelatin or hyaluronic acid matrix), and the gel is cultured in an incubator to promote cell growth. The invention will be of use in cell growth for the purposes of implantation in cutaneous, cartilaginous, gingival and bone lesions, inter alias, and in the field of tissue engineering.
    Type: Application
    Filed: August 3, 2012
    Publication date: August 28, 2014
    Inventors: Manuel Eduardo Young Anze, Carolina Ruth Weinstein Oppenheimer, Donald Irving Brown Gonzalez, Miguel Angel Fuentes Chandia, Ricardo Andres Ceriani Fernandez, Fernando Antonio Albornoz Marquez, Cristian Andres Acevedo Gutierrez
  • Publication number: 20140242044
    Abstract: An implant for deployment in select locations or select tissue for regeneration of tissue is disclosed. The implant includes collagen and or other bio-resorbable materials, where the implant may also be used for therapy delivery. Additionally, the implant may include, or have blended in, an additive, such as an osteoinductive factor, for example biocompatible ceramics and glass.
    Type: Application
    Filed: May 6, 2014
    Publication date: August 28, 2014
    Applicant: Kensey Nash BVF Technology LLC
    Inventors: Douglas G. EVANS, Scott M. Goldman, Russell T. Kronengold
  • Publication number: 20140234292
    Abstract: There is disclosed a method of preparing a plasma protein-containing medicament from citrated plasma or from a citrate-containing plasma fraction, the medicament being substantially free from undesired metals, which method comprises the following steps exchanging the citrate and optionally citrate-bound metals in a plasma-protein-containing solution for a water-soluble mono- or dicarboxylate or for an organic mono- or dicarboxylic acid under non-precipitating conditions, recovering the plasma protein or the plasma proteins, and finishing the medicament.
    Type: Application
    Filed: April 29, 2014
    Publication date: August 21, 2014
    Applicant: Baxter Innovations GmbH
    Inventors: Wolfgang Teschner, Yendra Linnau, Sonja Svatos, Herwig Igel
  • Publication number: 20140234432
    Abstract: Methods for controlling bleeding (e.g., enhancing coagulation and reducing fibrinolysis) in a subject are disclosed. The methods include selecting a subject in need of enhanced coagulation or reduced fibrinolysis, and administering to the subject a carbon monoxide releasing molecule (CORM). Examples of CORMs include tricarbonyldichlororuthenium (II) dimer, tricarbonylchloro-(glycinato)ruthenium (II), sodium boranocarbonate, dimanganese decacarbonyl, and iron pentacarbonyl. Further disclosed are compositions and methods for treating a subject in need of a blood product by administering to the subject a composition including a CORM and a blood product (e.g., cryoprecipitate or fresh frozen plasma).
    Type: Application
    Filed: February 21, 2014
    Publication date: August 21, 2014
    Applicant: THE UAB RESEARCH FOUNDATION
    Inventors: Vance G. Nielsen, James F. George, James K. Kirklin
  • Publication number: 20140186455
    Abstract: An implant for promoting accelerated wound healing. The implant comprises a non-flocculating fiber material, admixed with a settable fluid. The fiber component typically will have short fiber lengths, so as to avoid forming entangled masses or clumps when mixed with a fluid. In an embodiment, the fiber material is native collagen fibers and the settable fluid is an isolated blood fraction, such as platelet rich plasma and platelet poor plasma. The native collagen fiber retaining the native crosslinks of the source tissue and providing an architectural and structural scaffolding for advancing cellular infiltration. The wound healing implant will accelerate the bodies healing process, to provide better healing and less scar tissue of the wound site.
    Type: Application
    Filed: December 31, 2012
    Publication date: July 3, 2014
    Inventors: Gino Bradica, Ryan Saska, Christopher DiJiacomo, Timothy A. Ringeisen
  • Publication number: 20140161899
    Abstract: The instant invention provides a method to reduce adverse events caused by a pharmaceutical preparation derived from a plasma fraction wherein the method comprises contacting the plasma fraction with heparin or a heparin-like substance thereby reducing the activity of at least one activated serine proteaseper ml of the plasma fraction.
    Type: Application
    Filed: May 14, 2012
    Publication date: June 12, 2014
    Inventors: Stefan Schulte, Uwe Kalina, Michael Moses, Annette Feussner
  • Patent number: 8734854
    Abstract: A sub-atmospheric, negative pressure is applied to a growth factor starting material, such as whole blood, to release growth factors and plasma in a non-destructive medium. The released growth factors having a weight of about 70-76 kDaltons are applied in either a filtered or unfiltered state to a wound to promote healing of the wound. The released growth factors are applied topically to the area of a surface wound to effect healing. The released growth factors are also injected into soft tissue, such as a torn tendon, to promote tissue growth and healing. The growth factors are released in one method from a patient's own blood. In another method the growth factors are released from a whole blood source and freeze dried by conventional lyophilization. Then at a later date, the freeze dried product is reconstituted by normal saline for treatment of a patient's wound or for use in a surgical procedure.
    Type: Grant
    Filed: July 9, 2009
    Date of Patent: May 27, 2014
    Inventors: James B. Gandy, Robert J. Brandt, Ryan N. Brandt, Clark Galen, Joseph F. Greco, John Kiwczak
  • Patent number: 8728466
    Abstract: This document provides methods and materials involved in treating burn injuries. For example, methods and materials for using skin grafts (e.g., autologous skin grafts) treated with an autologous platelet concentrate and autologous thrombin to treat burn injuries (e.g., deep skin burn injuries) are provided.
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: May 20, 2014
    Assignee: University Hospital Ostrava
    Inventors: Vaclav Prochazka, Hana Klosova, Giannoula Lakka Klement
  • Patent number: 8728532
    Abstract: The invention provides for ischemia/reperfusion protection compositions having one or more ketone bodies and melatonin. The invention also provides for methods of using such compositions to reduce or prevent ischemia/reperfusion injury due to blood loss, stroke or cardiopulmonary arrest or surgery.
    Type: Grant
    Filed: April 11, 2008
    Date of Patent: May 20, 2014
    Assignee: Regents of the University of Minnesota
    Inventors: Matthew T. Andrews, Lester R. Drewes, Greg Beilman
  • Patent number: 8709492
    Abstract: There is disclosed a method of preparing a plasma-protein-containing medicament from citrated plasma or from a citrate-containing plasma fraction, the medicament being substantially free from undesired metals, which method comprises the following steps: exchanging the citrate and optionally citrate-bound metals in a plasma-protein-containing solution for a water-soluble mono- or dicarboxylate or for an organic mono- or dicarboxylic acid under non-precipitating conditions, recovering the plasma protein or the plasma proteins, and finishing the medicament.
    Type: Grant
    Filed: June 14, 2005
    Date of Patent: April 29, 2014
    Assignee: Baxter Aktiengesellschaft
    Inventors: Wolfgang Teschner, Yendra Linnau, Sonja Svatos, Herwig Igel
  • Publication number: 20140112890
    Abstract: The invention features the production of an amine-reactive proteoglycan, specifically chondroitin sulfate or hyaluronic acid. This material can be provided in powder (solid) or liquid form and combined with blood derivatives including serum, platelets, platelet rich plasma, bone marrow, or with other tissue products to form hydrogels. The properties (physical and biological) are different for each of these hydrogels and can be further manipulated by controlling the conditions under which the hydrogels are formed. Such properties include the biodegradability of the hydrogel, the compressibility, the adhesive strength, the presence of pharmaceutical agents or therapeutic cells, and resiliency.
    Type: Application
    Filed: April 2, 2012
    Publication date: April 24, 2014
    Applicant: The John Hopkins University
    Inventors: Jennifer H. Elisseeff, Iossif Strehin
  • Publication number: 20140105997
    Abstract: The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer.
    Type: Application
    Filed: December 27, 2013
    Publication date: April 17, 2014
    Applicant: ECONUGENICS, INC.
    Inventor: Isaac ELIAZ
  • Publication number: 20140099293
    Abstract: A method of prevention/treatment of pathological consequences of DNA damage triggered by incorporation of circulating apoptotic chromatin fragments into healthy cells of individuals/patients in need therefore, said method comprising ex vivo or extra corporeal treatment of blood/plasma for removal of circulating chromatin fragments released from apoptotic cells which apoptotic chromatin fragments are capable of triggering DNA damage leading to genomic instability, senescence, apoptosis and cancerous transformation of healthy cells on being integrated into their genomes
    Type: Application
    Filed: December 9, 2013
    Publication date: April 10, 2014
    Applicant: Tata Memorial Centre
    Inventors: Indraneel MITTRA, Urmila Chandrashekhar SAMANT, Gopesh Kumar MODI, Pradyumna Kumar MISHRA, Gobichettipalayam Subbaratnam BHUVANESHWAR
  • Publication number: 20140083945
    Abstract: Focal segmental glomerulosclerosis (FSGS) is a common cause of proteinuric kidney disease, which comprises both native and transplanted kidneys. Treatment was limited in the past due to the complicated pathogenesis of FSGS, including previously unidentified serum factors. Here, serum soluble urokinase receptor (suPAR) is reported to be elevated in FSGS patients but not in patients with other primary glomerular diseases. Higher pre-transplantation suPAR levels are associated with risk for FSGS recurrence in kidney grafts. Renal disease only develops when suPAR sufficiently activates podocyte ?3 integrin. Thus, disease pathogenesis can be stopped or slowed by ex vivo removal of suPAR from a subject's circulation. Removal may be measured by comparing the level (e.g., amount or concentration) of suPAR before and after such treatment.
    Type: Application
    Filed: May 9, 2012
    Publication date: March 27, 2014
    Inventor: Jochen Reiser
  • Patent number: 8673361
    Abstract: The invention relates to an agent having cytokine mediating activity. In particular the invention relates to a composition comprising a fraction of denatured plasma proteins and at least one metal, metal ion or metal salt thereof, wherein said mixture has cytokine mediating activity.
    Type: Grant
    Filed: April 27, 2007
    Date of Patent: March 18, 2014
    Assignee: Cambridge Scientific Pty Ltd
    Inventor: Maud Louisa Johanna Maria Eijkenboom
  • Publication number: 20140065106
    Abstract: The present disclosure generally relates to tissue engineering and wound healing. More particularly, the present disclosure relates to the modification of plasma with a stability conferring agent to create a hydrogel for use in regenerative medicine and other tissue engineering applications.
    Type: Application
    Filed: August 20, 2013
    Publication date: March 6, 2014
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Laura Suggs, Shanmugasundaram Natesan, Robert Christy, David Zamora
  • Publication number: 20140065121
    Abstract: The present disclosure generally relates to tissue engineering and wound healing. More particularly, the present disclosure relates to the modification of plasma with a stability conferring agent to create a hydrogel for use in regenerative medicine and other tissue engineering applications.
    Type: Application
    Filed: August 20, 2013
    Publication date: March 6, 2014
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Laura Suggs, Shanmugasundaram Natesan, Robert Christy, David Zamora